In a phase I clinical trial (NCT02321293), the aim of co-administration of Cur and TKIs for EGFR-mutant-advanced NSCLC was to assess the safety and feasibility of using Cur in conjunction with an EGFR-TKI in patients with advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.